Ann: RAD201 HER2 nanobody demonstrates favourable tumor targeting, page-11

Sorry mate but Dual listing small caps at this end of the market is a waste of money. Awareness comes from clinical studies and publications, exchange listings of tiny small cap companies only attracts minnows to trade for pips.

NASDAQ listing is very expensive both one time CAPEX and Opex costs. OTC markets are bone dry due to the current fed rate which has decimated all growth and tech stocks.

Board and management just need to focus on proving the science - share price appreciation will follow meaningful clinical
evidence.